330786-25-9

中文名稱 4-氨基-1-環(huán)戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶

英文名稱 PCI 29732

CAS 330786-25-9

分子式 C22H21N5O

分子量 371.43

MOL 文件 330786-25-9.mol

更新日期 2024/12/03 15:40:33

330786-25-9 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 4-氨基-1-環(huán)戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶價格(試劑級) 常見問題列表

基本信息

中文別名

化合物PCI29732
4-氨基-1-環(huán)戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶

英文別名

CS-2698
PCI 29732
PCI 29732
PCI29732
PCI-29732
PCI 29732 (This product is only available in Japan.)
1-Cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
4-Amino-1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine
1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-cyclopentyl-3-(4-phenoxyphenyl)-

所屬類別

生物化工：激動劑抑制劑

物理化學(xué)性質(zhì)

沸點599.6±50.0 °C(Predicted)

密度1.36±0.1 g/cm3(Predicted)

儲存條件-20°C儲存

溶解度DMF: 20 mg/ml; DMF:PBS (pH 7.2) (1:2): 0.3 mg/ml; DMSO: 10 mg/ml; Ethanol: 5 mg/ml

酸度系數(shù)(pKa)4.24±0.30(Predicted)

形態(tài)粉末

顏色White to off-white

安全數(shù)據(jù)

危險性符號(GHS) 有害 (GHS07)

GHS07

警示詞警告

危險性描述H302-H315-H319-H335

防范說明P261-P305+P351+P338

圖譜信息

4-氨基-1-環(huán)戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶(330786-25-9)核磁圖(¹HNMR)

4-氨基-1-環(huán)戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶價格(試劑級)

報價日期	產(chǎn)品編號	產(chǎn)品名稱	CAS號	包裝	價格
2026/07/06	S6725	4-氨基-1-環(huán)戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶 PCI 29732	330786-25-9	2mg	1050.21元
2026/06/05	HY-18010	4-氨基-1-環(huán)戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶 PCI 29732	330786-25-9	5mg	740元
2026/06/05	HY-18010	4-氨基-1-環(huán)戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶 PCI 29732	330786-25-9	10mM * 1mLin DMSO	814元

常見問題列表

生物活性

PCI 29732是一種選擇性的、不可逆的Btk抑制劑，IC50為0.5 nM。

靶點

Target	Value
BTK (Cell-free assay)	0.5 nM
BLK (Cell-free assay)	0.5 nM
Bmx (Cell-free assay)	0.8 nM
EGFR (Cell-free assay)	5.6 nM
YES (Cell-free assay)	6.5 nM

體外研究

PCI29732 shows cytotoxicity in different cells. The IC ₅₀ values are 7.94 μM for S1, 7.79 μM for S1-MI-80, 6.55 μM for H460, 6.34 μM for H460/MX20, 6.14 μM for KB, 6.02 μM for KBv200, 12.45 μM for HEK293/pcDNA3, 14.58 μM for HEK293-ABCG2-482-R2, and 13.24 μM for HEK293-ABCG2-482-T7 cells.
PCI-29732 blocks the transcriptional up-regulation of a panel of B-cell activation genes in human CD20+ B cells stimulated at the B-cell antigen receptor (BCR).

體內(nèi)研究

PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents.
PCI 29732 (20 mg/kg; p.o.; every 3 d × 5 times) enhances the anticancer efficacy of Topotecan in the H460/MX20 cell xenograft nude mice model.

Animal Model:	5-6 weeks old athymic nude mice (bearing H460/MX20 cells)
Dosage:	20 mg/kg (combination with Topotecan; every 3 d × 5 times, i.p., 3 mg/kg; topotecan was given 1 h after PCI29732 administration)
Administration:	P.o.; every 3 d × 5 times
Result:	Significant reductions in tumor weight and volume were observed in the group treated with PCI29732 in combination with Topotecan.